Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 30, 2023

Mosunetuzumab in Patients With Relapsed/Refractory DLBCL Treated With ≥2 Prior Lines of Therapy

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Blood Adv 2023 Apr 17;[EPub Ahead of Print], NL Bartlett, S Assouline, P Giri, SJ Schuster, CYY Cheah, MJ Matasar, GP Gregory, DH Yoon, M Shadman, K Fay, SS Yoon, C Panizo, IW Flinn, A Johnston, F Bosch, LH Sehn, MC Wei, S Yin, I To, CC Li, H Huang, A Kwan, E Penuel, EE Budde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading